Project Grant R43DK139922
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $284,517 Project Grant (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) to Electronic Biosciences, Inc. to develop a point-of-care diagnostic assay for detecting autoantibodies associated with type 1 diabetes (T1D). This project aims to leverage nanopore technology to create a rapid, cost-effective test for screening populations, especially children, for T1D biomarkers that appear...
- This federal Project Grant award of $801,662, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research by the Scripps Research Institute to investigate the early phase of type 1 diabetes. The key objectives are to characterize the antigen-presenting cells associated with pancreatic islets during the pre-diabetic stage in mice, using advanced techniques...
- This $882,180 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support a comprehensive research effort to analyze the largest dataset of rare genetic variants associated with diabetes. The Broad Institute, Inc. will lead this project to assess variant penetrance and integrate the genomic data with high-throughput cellular assays to...
- This $451,000 Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant will fund research to investigate the role of microRNAs in adipose tissue from people with HIV who develop type 2 diabetes. The project aims to evaluate microRNA expression in adipose tissue and explore whether circulating microRNAs in plasma could serve as biomarkers of risk...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $235,403 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The Johns Hopkins University. The funding will support the development of a membrane-reconstituted ZNT8 biosensor to detect cell-surface ZNT8 autoantibodies in the peripheral blood of patients with type-1 diabetes. This novel bioanalytical tool aims to enable the early detection of islet...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $621,794 Project Grant to Islex Therapeutics, LLC on August 1, 2025. The grant supports the preclinical development of a therapeutic antibody for treating type 1 diabetes (T1D), a chronic autoimmune disease affecting approximately 1.5 million Americans. The objective is to establish proof-of-principle for a humanized...
- This Project Grant award of $107,948 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award will fund research at Case Western Reserve University (CWRU) to investigate the role of microRNA146a (miR146a) in regulating autoimmunity in Type 1 Diabetes (T1D). The project aims to study how miR146a deficiency impacts T cell autoreactivity and T regulatory cell...
- This $2,263,983 Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to develop "engineered regulatory T cells (Tregs)" as an immunotherapy for type 1 diabetes. The central goal is to create antigen-specific Tregs that can more effectively suppress the autoimmune destruction of insulin-producing beta cells. The research...
- The Project Grant award of $324,793 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant was awarded to Nucb1 Holdings LLC on September 1, 2025 with an expected completion date of August 31, 2026. The purpose of the grant is to develop a platform technology for discovering conformation-specific, anti-protofibril monoclonal antibodies (mAbs) that target...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $726,922 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Beckman Research Institute of the City of Hope. The grant will fund research examining the role of chromatin remodeling factors, specifically the protein JARID2, in modulating inflammatory processes that contribute to diabetic microvascular complications such as retinopathy and...
This $291,949 Project Grant was awarded on September 15, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant was awarded to Biosettia Inc. (UEI: GZM5S2UYEGD2) located in San Diego, CA to support research aimed at using deep sequencing to measure variants of the endogenous retrovirus (ERV) GAG gene as potential biomarkers for type 1 diabetes. The project seeks to further investigate the connection between abnormal ERV GAG gene variants and autoimmune activation in a non-obese diabetic (NOD) mouse model and human type 1 diabetes patients, with the goal of developing a sequencing-based biomarker that could aid in screening high-risk children, staging pre-diabetic patients, and predicting disease onset.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $291.9k | 9/17/25 |